Ventricular remodeling is a compensatory response that comprises the processes of apoptosis, muscle cell hypertrophy, and rearrangement of the extracellular matrix fibers connecting the muscles. These processes are associated with transformation of endothelium and/or fibroblasts to myofibroblasts. Neutral matrix metalloproteinases, membrane type matrix metalloproteinases, and disintegrin metalloproteinase play a significant role in these processes. The cell-extracellular matrix connections are important in maintaining and synchronizing muscle function. However, a complete extracellular matrix-cell disconnect leads to a decrease in muscle cell strength, apoptosis, and hypertrophy.
3. Aimes RT, Quigley JP. MMP-2 is an interstitial collagenase. J Biol Chem270:5872-5876.
4.
4. Tyagi SC, Bheemanathini VS, Mandi S, Reddy HK, Voelker DJ. Role of extracellular matrix metalloproteinases in cardiac remodeling. Heart Failure Reviews1:73-80.
5.
5. Uemura S, Matsushita H, Li W, Glassford AJ, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: Role of oxidative stress. Circ Res88:1291-1298.
6.
6. Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem47: 230-235, 1991.
7.
7. Greene J, Wang M, Liu TE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human TIMP-4. J Biol Chem271:30375-30380.
8.
8. Tummalapalli CM, Heath BJ, Tyagi SC. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem80(4):512-521, 2001.
9.
9. Mujumdar VS, Tyagi SC. Temporal regulation of ECM components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertension17:261-270.
10.
10. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of TIMP-1, -2, -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest101:1478-1487.
11.
11. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of TIMP-1 for a wide range of cells. FEBS Lett298:29-32.
12.
12. Nemeth JA, Goolsby CL. TIMP-2, a growth-stimulatory protein from SV40 transformed human fibroblasts. Exp Cell Res207:376-382.
13.
13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med341:709-717.
14.
14. McFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen tumouver, improves heart rate variability and reduces early moming rise in heart rate in heart failure patients. Cardiovasc Res35:30-34.
15.
15. Sorbi D, Fadly M, Hicks R, Elaxander S, Arbeit L. Captopril inhibits the 72 kda and 92 kda matrix metallo proteinase. Kidney Intern44:1266-1272.
16.
16. Reinhardt D, Sigusch HH, Henbe J, Tyagi SC, Korfer R, Figulla HR. Cardiac remodeling in end stage heart failure: Upregulation of MMP irrespective of the underlying disease and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart “in press,” 2002.
17.
17. Tyagi SC, Lewis K, Pikes D, et al. Stretch induced membrane type matrix metalloproteinases and tissue plasminogen activator in cardiac fibroblast cells. J Cell Physiol176:374-382.
19. Lee AA, Delhaas T, McCulloch AD, Villarreal FJ. Differential responses of adult cardiac fibroblasts to in vitro biaxial strain patterns. J Mol Cell Cardiol31(10):1833-1843, 1999.
20.
20. Nagatomo Y, Carabello BA, Coker ML, et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol278:H151-161, 2000.
21.
21. Janicki JS, Brower GL, Henegar JR, Wang L. Ventricular remodeling in heart failure: The role of myocardial collagen. Adv Exp Med Biol382:239-245.
22.
22. Namba T, Tsutsui H, Tagawa H, et al. Regulation of fibrillar collagen gene expression and protein accumulation in volume-overloaded cardiac hypertrophy. Circulation95:2448-2454.
23.
23. Cox MJ, Sood HS, Hunt MJ, Chandler D, Henegar JR, Aru GM, Tyagi SC.Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol282:H1197-H1205, 2002.
24.
24. Meredith Jr JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell sirvival factor. Mol Biol Cell4:953-961.
25.
25. Juliano RL, Haskill S. Signal tranduction from the extra cellular matrix. J Cell Biol120:577-585.
26.
26. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate TIMPs and disintigrin metallo proteinase in cardiac cells. Cardiovasc Res42:162-172.
27.
27. Hoppeler H, Kayar SR, Capillary and oxidative capacity of muscles. News in Physiol Sci3:113-116.
28.
28. Senior RM, Griffin GL, Eliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. Human 92-and 72-kilodalton type IV collagenases are elastases. J Biol Chem266:7870-7875.
29.
29. Rucklidge GJ, Milne G, McGaw BA, Milne E, Robins SP. Turnover rates of different collagen types measured by isotope ratio mass spectrometry. Biochim Biophys Acta11:1156-1157.
30.
30. Tyagi SC, Ratajska A, Weber KT. Myocardial matrix metalloproteinases: localization and activation. Mol Cell Biochem126:49-59.
31.
31. Zhang H, Schmeisser A, Garlichs CD, et al. Angiotensin IL-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH/ NADPH-oxidases. Cardiovasc Res44:215-222.
33. Ricciarelli R, Maroni P, Ozer N, Zingg JM, Azzi A. Agerelated increase of collagenase expression can be reduced by alpha-tocopherol via PKC inhibition. Free Radic Biol Med27(7-8):729-737, 1999.
34.
34.Hunt MJ, Aru GM, Hayden MR, Moore CK, Hoit BD, Tyagi SC. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol283:L239-L245, 2002.
35.
35. Rohde LE, et al. MMP inhibitors attenuates early LV enlargement in experimental MI in mice. Circulation99:3063-3070.
36.
36. Spinale FG, et al. MMP inhibition during congestive heart failure. Cir Res85:364-376.
37.
37. Li Hua, Simon H, Cocan TMA, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ACE and MMP-inhibition. Cardiovasc Res46:298-306.
38.
38. Sensaki H, Paolocci N, Gluzband Y, et al. B-blockade prevents sustained MMP activation and diastolic stiffening induced by AnglI combined with evolving cardiac dysfunction. Cir Res86:807-815.
39.
39. Bernstein M, Tyagi SC. j-blocker improves cardiac function by reducing oxidative stress and metalloproteinase activity post myocardial infarction. J Appl Res1(2):144-152, 2001.
40.
40. Bowes J, McDonald MC, Piper J, Thiemermann C. Inhibitors of poly (ADP-ribose)synthetase protect rats cardiomyocytes against oxidant stress. Cardiovasc Res41(1):126-134, 1999.
41.
41. Tyagi SC, Kumar SG, Alla SR, Reddy HK, Voelker DJ, Janicki JS. Extracellular matrix regulation of metalloproteinase and antiproteinase in human heart fibroblast cells. J Cell Physiol167:137-147.
42.
42. Mujumdar VS, Aru GM, Tyagi SC. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem82(3):491-500, 2001.
43.
43. McElmurray JH, Mukherjee R, New RB, et al. ACEI and MMP inhibition with developing heart failure: Comparative effects on LV function and geometry. J Pharmacol Exp Ther291:799-811.
44.
44. Turcani M, Jacob R. Minoxidil accelerates heart failure development in rats with ascending aortic constriction. Can J Physiol Pharmacol76:613-620.
45.
45. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation. Nature Med4(10):1200-1200, 1998.
46.
46. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of MMP-9 attenuates LV enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest106(1):55-62, 2000.
